Results 271 to 280 of about 292,639 (396)

Treatment of Pyoderma Gangrenosum With Bimekizumab

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Pyoderma gangrenosum (PG) is an inflammatory neutrophilic dermatosis with no FDA‐approved treatments. Current therapies, including corticosteroids and immunomodulators, often show limited efficacy and nonspecific, conferring to higher risk of adverse events.
Kareena S. Garg   +2 more
wiley   +1 more source

The Hypolipemic Properties of Kaempferol Presented in Microwaved Cooked Broccoli Between Hyperlipidemic Rat Models. [PDF]

open access: yesFood Sci Nutr
Ali AA   +7 more
europepmc   +1 more source

[Properties and mechanism of hyperlipidemia induced in rabbits by tributyltin fluoride].

open access: bronze, 1982
Hisao Matsui   +5 more
openalex   +2 more sources

Pyoderma Gangrenosum Associated With Major Adverse Cardiovascular Events

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a neutrophilic dermatosis characterized by the rapid onset of painful ulcers. Previous retrospective population‐based studies have identified a relationship between PG and major adverse cardiovascular events (MACE).
Nana Ama Adjei‐Frimpong   +3 more
wiley   +1 more source

Effect of γ-Oryzanol on Hyperlipidemia

open access: bronze, 1981
Hiroshi Oimatsu   +3 more
openalex   +2 more sources

Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real‐World Experience From the Nationwide Taiwan Hepatitis C Virus Registry

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Hepatitis C virus (HCV) infection is associated with an increased risk of cardiovascular disease (CVD); however, the impact of interferon (IFN)‐based therapy on cardiovascular outcomes remains unclear. This nationwide cohort study included 7411 patients with HCV from The Taiwanese Chronic Hepatitis C Cohort registry who received IFN‐based ...
Ping‐Jen Hu   +42 more
wiley   +1 more source

Home - About - Disclaimer - Privacy